News
Trial results, approvals, pricing changes, safety findings and market moves across peptides and GLP-1 medications — each traced to a primary source, each dated. For enforcement actions specifically, see the regulatory tracker.
- Trial results
- Approvals
- Pricing changes
- Safety findings
-
A Boys & Girls Club programme moved children’s BMI scores, but not their drinks
Read more: A Boys & Girls Club programme moved children’s BMI scores, but not their drinksChildren at Massachusetts Boys & Girls Clubs that ran a six-week programme called H2GO! ended the year with a lower BMI z score than children at clubs that did not, according to a cluster randomised trial published in JAMA Network Open on 1 October 2026. The difference was small and only just statistically significant, and…
-
The Wegovy pill nearly matched the injection’s new starts within 12 weeks
Read more: The Wegovy pill nearly matched the injection’s new starts within 12 weeksWithin twelve weeks of its approval for weight management, the semaglutide pill was being started almost as often as the injection. A research letter in JAMA Network Open, drawn from the medical records of nearly 48 million US adults who qualified for an obesity drug, counted 148,792 people who began oral semaglutide between 22 December…
-
UBT251, a triple-agonist injection, cut weight by up to 19.7% in 24 weeks
Read more: UBT251, a triple-agonist injection, cut weight by up to 19.7% in 24 weeksUBT251, an experimental once-weekly injection that acts on three hormone receptors, lowered body weight by between 13.6% and 19.7% over 24 weeks, against 2.0% on placebo, in a phase 2 trial of 205 adults in China published in Cell Metabolism on 7 October. It uses the same three-receptor approach as Lilly’s retatrutide. For patients, nothing…
-
WHO’s first child obesity guidelines rule out weight-loss drugs before age 10
Read more: WHO’s first child obesity guidelines rule out weight-loss drugs before age 10The World Health Organization published its first guidelines on obesity in children and adolescents on 7 October, as two separate documents: one for children up to the age of 9 and one for adolescents aged 10 to 19. Both put structured diet, physical activity and behaviour-change programmes at the centre of care. For children under…
-
Every berberine trial in PMOS failed an integrity check
Read more: Every berberine trial in PMOS failed an integrity checkAustralian researchers set out to pool the randomised trials of berberine in polyendocrine metabolic ovarian syndrome, or PMOS, the condition previously called polycystic ovary syndrome. Earlier reviews had presented the supplement as a match for metformin. Every eligible trial, four of them covering 452 women, was rated at high risk of compromised integrity, so none…
-
Chemically made semaglutide matched Wegovy in a 462-person trial in China
Read more: Chemically made semaglutide matched Wegovy in a 462-person trial in ChinaA chemically synthesised version of semaglutide, developed by the Chinese drugmaker CSPC under the code HD1916, produced weight loss equivalent to Wegovy in a 44-week randomised trial of 462 Chinese adults with obesity, published on 7 October in Diabetes, Obesity and Metabolism. For readers in the US nothing changes yet: HD1916 is not approved here,…
-
Three years on tirzepatide: how much weight came back from the low point
Read more: Three years on tirzepatide: how much weight came back from the low pointMost adults who stayed on tirzepatide for three years in the SURMOUNT-1 trial put back only a small part of what they had lost after reaching their lowest weight, according to a post hoc analysis published in Obesity Pillars. Of 690 participants with prediabetes who took at least three-quarters of their doses and lost at…
-
A second compounded glutathione recall in a month, after two emergency visits
Read more: A second compounded glutathione recall in a month, after two emergency visitsGreenwich Rx, a 503A compounding pharmacy in Tomball, Texas, is recalling ten lots of compounded glutathione injection nationwide because of potentially elevated endotoxin levels. The company says it has received two reports of patients who needed emergency department care after a glutathione product was given intravenously, although the product was not formulated for IV use.…
-
Diabetes consensus moves GLP-1 drugs earlier, potentially to diagnosis
Read more: Diabetes consensus moves GLP-1 drugs earlier, potentially to diagnosisThe American Diabetes Association and the European Association for the Study of Diabetes have published their first update since 2022 of their joint consensus on managing type 2 diabetes, and it advocates using GLP-1-based drugs or SGLT2 inhibitors earlier, potentially from diagnosis, to protect the heart and kidneys. The report appeared in Diabetologia on 2…
-
Orforglipron cleared its heart-safety bar against insulin in 2,749 adults
Read more: Orforglipron cleared its heart-safety bar against insulin in 2,749 adultsOrforglipron, Eli Lilly’s once-daily GLP-1 pill, did not raise the risk of heart attack, stroke or cardiovascular death compared with insulin glargine in 2,749 adults with type 2 diabetes and established heart or kidney disease, according to the ACHIEVE-4 trial published in The Lancet on 30 September. It is the first cardiovascular-outcomes trial of a…